

# Nikolaos Papagiannakis

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6415967/publications.pdf>

Version: 2024-02-01

34  
papers

664  
citations

759055

12  
h-index

642610

23  
g-index

37  
all docs

37  
docs citations

37  
times ranked

912  
citing authors

#	ARTICLE	IF	CITATIONS
1	Motor and Nonmotor Features of Carriers of the p.A53T Alpha-Synuclein Mutation: A Longitudinal Study. <i>Movement Disorders</i> , 2016, 31, 1226-1230.	2.2	134
2	Long Non-coding RNAs Associated With Neurodegeneration-Linked Genes Are Reduced in Parkinson's Disease Patients. <i>Frontiers in Cellular Neuroscience</i> , 2019, 13, 58.	1.8	63
3	Lysosomal alterations in peripheral blood mononuclear cells of Parkinson's disease patients. <i>Movement Disorders</i> , 2015, 30, 1830-1834.	2.2	53
4	Circulating Brain-Enriched MicroRNAs for Detection and Discrimination of Idiopathic and Genetic Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 457-467.	2.2	43
5	Differentially Expressed Circular <i>sc</i> RNAs in Peripheral Blood Mononuclear Cells of Patients with Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 1170-1179.	2.2	38
6	Validation of differentially expressed brain-enriched microRNAs in the plasma of PD patients. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1594-1607.	1.7	36
7	Alpha-synuclein dimerization in erythrocytes of patients with genetic and non-genetic forms of Parkinson's Disease. <i>Neuroscience Letters</i> , 2018, 672, 145-149.	1.0	35
8	Selective cognitive impairment and hyposmia in p.A53T <i>SNCA</i> PD vs typical PD. <i>Neurology</i> , 2018, 90, e864-e869.	1.5	28
9	Frontotemporal dementia as the presenting phenotype of p.A53T mutation carriers in the alpha-synuclein gene. <i>Parkinsonism and Related Disorders</i> , 2017, 35, 82-87.	1.1	27
10	The relationship between environmental factors and different Parkinson's disease subtypes in Greece: Data analysis of the Hellenic Biobank of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 67, 105-112.	1.1	21
11	Autophagy dysfunction in peripheral blood mononuclear cells of Parkinson's disease patients. <i>Neuroscience Letters</i> , 2019, 704, 112-115.	1.0	21
12	Phenotypic Characteristics in GBA-Associated Parkinson's Disease: A Study in a Greek Population. <i>Journal of Parkinson's Disease</i> , 2018, 8, 101-105.	1.5	18
13	Sublingual microcirculatory alterations during the immediate and early postoperative period: A systematic review and meta-analysis. <i>Clinical Hemorheology and Microcirculation</i> , 2022, 80, 253-265.	0.9	14
14	Microcirculation-guided treatment improves tissue perfusion and hemodynamic coherence in surgical patients with septic shock. <i>European Journal of Trauma and Emergency Surgery</i> , 2022, 48, 4699-4711.	0.8	13
15	Peripheral alpha-synuclein levels in patients with genetic and non-genetic forms of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020, 73, 35-40.	1.1	12
16	Serum Uric Acid Level as a Biomarker in Idiopathic and Genetic (p.A53T Alpha-Synuclein Carriers) Parkinson's Disease: Data from the PPMI Study. <i>Journal of Parkinson's Disease</i> , 2020, 10, 481-487.	1.5	12
17	Clinical practice recommendations on the management of perioperative cardiac arrest: A report from the PERIOPCA Consortium. <i>Critical Care</i> , 2021, 25, 265.	2.5	10
18	Circulating suPAR associates with severity and in-hospital progression of COVID-19. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13794.	1.7	10

#	ARTICLE	IF	CITATIONS
19	123Iâ€”FPâ€”CIT SPECT [(123) Iâ€”2Iâ€”2â€”carbomethoxyâ€”3Iâ€”2â€”(4â€”iodophenyl)â€”Nâ€”(3â€”fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T Î±â€”synuclein Parkinson's disease cohort versus Parkinson's disease. <i>Movement Disorders</i> , 2018, 33, 1734-1739.	2.2	9
20	Serum uric acid level as a putative biomarker in Parkinson's disease patients carrying GBA1 mutations: 2-Year data from the PPMI study. <i>Parkinsonism and Related Disorders</i> , 2021, 84, 1-4.	1.1	9
21	Apathy: An underestimated feature in GBA and LRRK2 non-manifesting mutation carriers. <i>Parkinsonism and Related Disorders</i> , 2021, 91, 1-8.	1.1	8
22	Determinants of venous return in steady-state physiology and asphyxia-induced circulatory shock and arrest: an experimental study. <i>Intensive Care Medicine Experimental</i> , 2022, 10, 13.	0.9	8
23	Assessment of Dynamic Changes in Stressed Volume and Venous Return during Hyperdynamic Septic Shock. <i>Journal of Personalized Medicine</i> , 2022, 12, 724.	1.1	8
24	REM sleep behavior disorder and other sleep abnormalities in p. A53T SNCA mutation carriers. <i>Sleep</i> , 2021, 44, .	0.6	6
25	Sinus bradycardia is associated with poor outcome in critically ill patients with COVID-19 due to the B.1.1.7 Lineage. <i>Toxicology Reports</i> , 2021, 8, 1394-1398.	1.6	6
26	DaTSCAN (123I-FP-CIT SPECT) imaging in early versus mid and late onset Parkinson's disease: Longitudinal data from the PPMI study. <i>Parkinsonism and Related Disorders</i> , 2020, 77, 36-42.	1.1	5
27	Association of Preoperative Basal Inflammatory State, Measured by Plasma suPAR Levels, with Intraoperative Sublingual Microvascular Perfusion in Patients Undergoing Major Non-Cardiac Surgery. <i>Journal of Clinical Medicine</i> , 2022, 11, 3326.	1.0	4
28	Serum Uric Acid in LRRK2 Related Parkinsonâ€™s Disease: Longitudinal Data from the PPMI Study. <i>Journal of Parkinson's Disease</i> , 2021, 11, 633-640.	1.5	3
29	Soluble Urokinase Receptor Levels Are Not Affected by the Systemic Inflammatory Response to Anesthesia and Operative Trauma. <i>European Surgical Research</i> , 2022, 63, 249-256.	0.6	3
30	Lipid level alteration in human and cellular models of alpha synuclein mutations. <i>Npj Parkinson's Disease</i> , 2022, 8, 52.	2.5	3
31	CSF and Circulating NfL as Biomarkers for the Discrimination of Parkinson Disease From Atypical Parkinsonian Syndromes. <i>Neurology: Clinical Practice</i> , 2021, 11, e867-e875.	0.8	2
32	Intrafamilial variability in a polish family harbouring a frameshift THAP1 mutation. <i>Journal of the Neurological Sciences</i> , 2018, 388, 158.	0.3	0
33	Autophagy-lysosome pathway as a source of candidate biomarkers for Parkinsonâ€™s disease. <i>Neuroimmunology and Neuroinflammation</i> , 0, 2020, .	1.4	0
34	Asymptomatic carriers of the p.A53T SNCA mutation: Data from the PPMI study. <i>Parkinsonism and Related Disorders</i> , 2022, 98, 72-74.	1.1	0